NDA 050356 · Ph Health
Coly-Mycin S
Colistin Sulfate, Hydrocortisone Acetate, Neomycin Sulfate, Thonzonium Bromide · Otic
Last checked: Nov 19, 2026Latest source record: Jan 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1962
May 17, 1962
Approved uses
1
Original approval plus efficacy supplements
Registered trials
94
39 Phase 3, 14 recruiting
FAERS reports
2
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 1, 2024.
INDICATIONS AND USAGE Cortisporin ® TC Otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 17, 1962 Original approval
1 products under this application
- COLY-MYCIN S · COLISTIN SULFATE EQ 3MG BASE/ML; HYDROCORTISONE ACETATE 10MG/ML; NEOMYCIN SULFATE EQ 3.3MG BASE/ML; THONZONIUM BROMIDE 0.5MG/ML · SUSPENSION/DROPS, OTIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Colistin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Ecological Effects of Decolonisation Strategies in Intensive CarePivotal-lookingCompleted
MJM BontenAcademic, hospital or other
NCT02208154 · 8,665 participants · Start Dec 1, 2013 · Primary completion Oct 27, 2017
Drug: Chlorhexidine oral care (CHX-Oro); Selective oropharyngeal decontamination (SOD) and 1 more · For: ICU-ecology (Multidrug Resistant Bacteria); ICU-acquired Bacteraemia
Sites: Edegem, Belgium; Ghent, Belgium; Liège, Belgium · 13 sites in all
- Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired InfectionsPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01798537 · 2,400 participants (planned) · Start Jun 2013 · Primary completion Jul 2015
Drug: Neomycin Colistin Nystatin Vancomycin · For: Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
Sites: Haifa, Israel
- Perioperative SDD to Prevent Infectious Complications After EsophagectomyPivotal-lookingRecruiting
Radboud University Medical CenterAcademic, hospital or other
NCT05865743 · 854 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2027
Drug: SDD · For: Esophageal Cancer
Sites: Leuven, Belgium; Nijmegen, Netherlands
Rambam Health Care CampusAcademic, hospital or other
NCT05922124 · 734 participants (planned) · Start Sep 1, 2024 · Primary completion Jul 2026
Drug: Cefiderocol; Ampicillin-sulbactam and 2 more · For: Carbapenem Resistant Bacterial Infection; Acinetobacter Bacteremia; Acinetobacter Pneumonia
Sites: Haifa, Israel; Ramat Gan, Israel; Tel Aviv, Israel
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsPivotal-lookingRecruiting
National University of SingaporeAcademic, hospital or other
NCT07004049 · 600 participants (planned) · Start Apr 21, 2025 · Primary completion Dec 31, 2028
Drug: Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline and 12 more · For: Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia and 2 more
Sites: Brisbane, Australia; Hangzhou, China; Xi'an, China · 41 sites in all
- Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled TrialPivotal-lookingRecruiting
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT06834971 · 508 participants (planned) · Start Jul 15, 2025 · Primary completion Sep 2026
Drug: Colistimethate sodium (CMS) · For: Ventilator-Associated Pneumonia (VAP)
Sites: Jinan, China
- Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?Pivotal-lookingTerminated
H. Jaap Bonjer, PhDAcademic, hospital or other
NCT01740947 · 485 participants · Start Jan 2013 · Primary completion Mar 2017
Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B) · For: Colorectal Cancer
Sites: Amsterdam, Netherlands; Haarlem, Netherlands; Hoofddorp, Netherlands · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthenia1
- central nervous system lymphoma1
- colitis1
- dehydration1
- diarrhoea1
- dizziness postural1
- dysstasia1
- endophthalmitis1
- fatigue1
- general physical health deterioration1
- malignant neoplasm progression1
- nausea1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, et al. · Lancet Infect Dis 2023 · Randomized Controlled Trial, Multicenter Study
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, et al. · Lancet Infect Dis 2025 · Clinical Trial, Phase III, Comparative Study
- ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
Righi E, Mutters NT, Guirao X, et al. · Clin Microbiol Infect 2023 · Systematic Review
- Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis.
Zhan Y, Mao W, Zhao C, et al. · BMC Infect Dis 2024 · Systematic Review, Meta-Analysis
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen.
Dubey V, Reza N, Hope W · Clin Microbiol Rev 2025 · Systematic Review
Sponsor: Ph Health
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.